SCHEMBL6153319

SCHEMBL6153319

CC(C)(CC(=O)c1cccc([N+](=O)[O-])c1)C(=O)O

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMO O15229 1/20 0.60
TP53 P04637 1/20 0.59
ALDH1A1 P00352 6/20 0.58
CES2 O00748 1/20 0.57
CES1 P23141 1/20 0.57
TSHR P16473 2/20 0.54
LMNA P02545 1/20 0.53
HPGD P15428 1/20 0.53
L3MBTL1 Q9Y468 1/20 0.53
KMT2A Q03164 4/20 0.51
MEN1 O00255 3/20 0.51
SMN1; SMN2 Q16637 2/20 0.51
HTT P42858 2/20 0.51
MITF O75030 1/20 0.51
HSP90AA1 P07900 1/20 0.51
MAPT P10636 1/20 0.51
NPSR1 Q6W5P4 1/20 0.51
GAA P10253 2/20 0.50
AGTR1 P30556 1/20 0.50
CYP1A2 P05177 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6153752 0.85 KMT2A (0.54) KMOTP53ALDH1A1CES2CES1
SCHEMBL5756510 0.82 CES2 (0.60) KMOTP53ALDH1A1CES2CES1
SCHEMBL6399354 0.81 TP53 (0.58) KMOTP53ALDH1A1CES2CES1
SCHEMBL211017 0.80 ALDH1A1 (0.67) KMOTP53ALDH1A1CES2CES1
SCHEMBL22347378 0.79 ALDH1A1 (0.58) KMOTP53ALDH1A1CES2CES1
SCHEMBL8850402 0.79 ALDH1A1 (0.58) KMOTP53ALDH1A1CES2CES1
SCHEMBL1986403 0.79 CES2 (0.70) KMOTP53ALDH1A1CES2CES1
SCHEMBL6678192 0.79 TP53 (0.63) KMOTP53ALDH1A1CES2CES1
SCHEMBL1420764 0.78 TP53 (0.67) KMOTP53ALDH1A1CES2CES1
SCHEMBL5500374 0.78 TP53 (0.67) KMOTP53ALDH1A1CES2CES1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050131242-A1 2-substituted vitamin d derivatives CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2005-06-16 US disclosed
US-20050059658-A1 Pyridazinone BAYER AKTIENGESELLSCHAFT (DE) 2005-03-17 US disclosed
EP-1499603-A1 ANTIVIRAL LACTONE-UREAS Bayer Aktiengesellschaft (DE) 2005-01-26 EP disclosed
EP-1404657-A1 PYRIDAZINONE Bayer HealthCare AG (DE) 2004-04-07 EP disclosed
WO-2003089421-A1 ANTIVIRAL LACTONE-UREAS BAYER HEALTHCARE AG (DE) 2003-10-30 WO disclosed
WO-2003002541-A1 PYRIDAZINONE BAYER HEALTHCARE AG (DE) 2003-01-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050059658-A1 Pyridazinone TYMP, TPMT, PDXK KMO 1228/4885TP53 1956/4885ALDH1A1 3281/4885
US-20050131242-A1 2-substituted vitamin d derivatives VDR, CYP2R1, CYP24A1 KMO 1904/4885TP53 4249/4885ALDH1A1 238/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.